LNP-mRNA Lung-Targeted Gene Delivery
Idiopathic Pulmonary Fibrosis · Lipid nanoparticle platform delivers therapeutic mRNA specifically to lung epithelium
Mechanism
Lipid nanoparticle platform delivers therapeutic mRNA specifically to lung epithelium
Development stage
Phase I (multiple)
Evidence level
Level 2 (Platform)
Developer
UT Southwestern / UCLA
Overview
SORT LNP technology enables organ-specific delivery. UCLA Feb 2026: full CFTR gene delivered to human airway cells via LNP. Platform technology applicable to any therapeutic gene — TERT, anti-fibrotic cytokines, reprogramming factors. Enables inhaled gene therapy without viral vectors.
Explore related
Medical disclaimer. This page summarizes research about LNP-mRNA Lung-Targeted Gene Delivery for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.